These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 28921911)
1. Update of Antitubercular Prodrugs from a Molecular Perspective: Mechanisms of Action, Bioactivation Pathways, and Associated Resistance. Laborde J; Deraeve C; Bernardes-Génisson V ChemMedChem; 2017 Oct; 12(20):1657-1676. PubMed ID: 28921911 [TBL] [Abstract][Full Text] [Related]
2. Insights on the Mechanism of Action of INH-C Vila-Viçosa D; Victor BL; Ramos J; Machado D; Viveiros M; Switala J; Loewen PC; Leitão R; Martins F; Machuqueiro M Mol Pharm; 2017 Dec; 14(12):4597-4605. PubMed ID: 29091448 [TBL] [Abstract][Full Text] [Related]
3. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis. Simões MF; Valente E; Gómez MJ; Anes E; Constantino L Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013 [TBL] [Abstract][Full Text] [Related]
4. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Unissa AN; Subbian S; Hanna LE; Selvakumar N Infect Genet Evol; 2016 Nov; 45():474-492. PubMed ID: 27612406 [TBL] [Abstract][Full Text] [Related]
5. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria. Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362 [TBL] [Abstract][Full Text] [Related]
6. Metabolism of the antituberculosis drug ethionamide. Vale N; Gomes P; Santos HA Curr Drug Metab; 2013 Jan; 14(1):151-8. PubMed ID: 23215813 [TBL] [Abstract][Full Text] [Related]
7. Drug resistance mechanism of PncA in Mycobacterium tuberculosis. Rajendran V; Sethumadhavan R J Biomol Struct Dyn; 2014; 32(2):209-21. PubMed ID: 23383724 [TBL] [Abstract][Full Text] [Related]
8. New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053. Chiarelli LR; Salina EG; Mori G; Azhikina T; Riabova O; Lepioshkin A; Grigorov A; Forbak M; Madacki J; Orena BS; Manfredi M; Gosetti F; Buzzi A; Degiacomi G; Sammartino JC; Marengo E; Korduláková J; Riccardi G; Mikušová K; Makarov V; Pasca MR ACS Infect Dis; 2020 Feb; 6(2):313-323. PubMed ID: 31729215 [TBL] [Abstract][Full Text] [Related]
9. Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis. Prieri M; Frita R; Probst N; Sournia-Saquet A; Bourotte M; Déprez B; Baulard AR; Willand N Eur J Med Chem; 2018 Nov; 159():35-46. PubMed ID: 30268015 [TBL] [Abstract][Full Text] [Related]
10. Correlation of pncA sequence with pyrazinamide resistance level in BACTEC for 21 mycobacterium tuberculosis clinical isolates. Mestdagh M; Realini L; Fonteyne PA; Rossau R; Jannes G; Mijs W; DE Smet KA; Portaels F; Van den Eeckhout E Microb Drug Resist; 2000; 6(4):283-7. PubMed ID: 11272256 [TBL] [Abstract][Full Text] [Related]
11. Mutation of katG in a clinical isolate of Mycobacterium tuberculosis: effects on catalase-peroxidase for isoniazid activation. Purkan ; Ihsanawati ; Natalia D; Syah YM; Retnoningrum DS; Kusuma HS Ukr Biochem J; 2016; 88(5):71-81. PubMed ID: 29235814 [TBL] [Abstract][Full Text] [Related]
12. Double prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents. Courtens C; Risseeuw M; Caljon G; Maes L; Cos P; Martin A; Van Calenbergh S Bioorg Med Chem Lett; 2019 May; 29(10):1232-1235. PubMed ID: 30879839 [TBL] [Abstract][Full Text] [Related]
13. Heterologous Expression of Ho VQT; Verboom T; Rong MK; Habjan E; Bitter W; Speer A Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495223 [TBL] [Abstract][Full Text] [Related]
15. Compounds for use in the treatment of mycobacterial infections: a patent evaluation (WO2014049107A1). Pechalrieu D; Lopez M Expert Opin Ther Pat; 2015 Jun; 25(6):729-35. PubMed ID: 25752488 [TBL] [Abstract][Full Text] [Related]
16. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. Lee KW; Lee JM; Jung KS J Korean Med Sci; 2001 Oct; 16(5):537-43. PubMed ID: 11641519 [TBL] [Abstract][Full Text] [Related]
17. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator. Engohang-Ndong J; Baillat D; Aumercier M; Bellefontaine F; Besra GS; Locht C; Baulard AR Mol Microbiol; 2004 Jan; 51(1):175-88. PubMed ID: 14651620 [TBL] [Abstract][Full Text] [Related]
18. Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates. Rueda J; Realpe T; Mejia GI; Zapata E; Rozo JC; Ferro BE; Robledo J Antimicrob Agents Chemother; 2015 Dec; 59(12):7805-10. PubMed ID: 26369965 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, anti-HIV and antitubercular activities of lamivudine prodrugs. Sriram D; Yogeeswari P; Gopal G Eur J Med Chem; 2005 Dec; 40(12):1373-6. PubMed ID: 16129516 [TBL] [Abstract][Full Text] [Related]